Sunshine Biopharma (SBFMW) EBIT (2016 - 2025)
Historic EBIT for Sunshine Biopharma (SBFMW) over the last 13 years, with Q3 2025 value amounting to -$1.1 million.
- Sunshine Biopharma's EBIT rose 178.42% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 3180.3%. This contributed to the annual value of -$5.8 million for FY2024, which is 2145.78% down from last year.
- Latest data reveals that Sunshine Biopharma reported EBIT of -$1.1 million as of Q3 2025, which was up 178.42% from -$2.1 million recorded in Q2 2025.
- In the past 5 years, Sunshine Biopharma's EBIT registered a high of -$279631.0 during Q4 2021, and its lowest value of -$23.4 million during Q4 2022.
- Over the past 5 years, Sunshine Biopharma's median EBIT value was -$1.2 million (recorded in 2022), while the average stood at -$2.3 million.
- As far as peak fluctuations go, Sunshine Biopharma's EBIT plummeted by 825515.73% in 2022, and later surged by 9491.85% in 2023.
- Over the past 5 years, Sunshine Biopharma's EBIT (Quarter) stood at -$279631.0 in 2021, then tumbled by 8255.16% to -$23.4 million in 2022, then skyrocketed by 94.92% to -$1.2 million in 2023, then tumbled by 71.64% to -$2.0 million in 2024, then skyrocketed by 46.68% to -$1.1 million in 2025.
- Its EBIT was -$1.1 million in Q3 2025, compared to -$2.1 million in Q2 2025 and -$1.3 million in Q1 2025.